Andreas Seeber

Andreas Seeber

Auto-generated profile, based on publicly available information

Andreas Seeber

Department of Internal Medicine V, Innsbruck Medical University and Tyrolean Cancer Research Institute, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2016
Verified
Journal Article
Closed access
AMAgnieszka Martowicz
Agnieszka Martowicz
ASAndreas Seeber
Andreas Seeber
GUGerold Untergasser
Gerold Untergasser

7 May 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ASAndreas Seeber
Andreas Seeber
AMAgnieszka Martowicz
Agnieszka Martowicz
GSGilbert Spizzo
Gilbert Spizzo
TBThomas Buratti
Thomas Buratti
POPeter Obrist
Peter Obrist
GUGerold Untergasser
Gerold Untergasser
EpCAM is highly expressed on membrane of epithelial tumor cells and has been detected as soluble/secreted (sEpCAM) in serum of cancer patients. In this study we established an ELISA for in vitro diagnostics to measure sEpCAM concentrations in ascites. Moreover, we evaluated the influence of sEpCAM levels on catumaxomab (antibody) - dependent cellular cytotoxicity (ADCC). Ascites specimens from cancer patients with positive (C+, n = 49) and negative (C-, n = 22) cytology and ascites of patients with liver cirrhosis (LC, n = 31) were collected. All cell-free plasma samples were analyzed for sEpCAM levels with a sandwich ELISA system established and validated by a human recombinant EpCAM standard for measurements in ascites as biological matrix. In addition, we evaluated effects of different sEpCAM concentrations on catumaxomab-dependent cell-mediated cytotoxicity (ADCC) with human peripheral blood mononuclear cells (PBMNCs) and human tumor cells. Our ELISA showed a high specificity for secreted EpCAM as determined by control HEK293FT cell lines stably expressing intracellular (EpICD), extracellular (EpEX) and the full-length protein (EpCAM) as fusion proteins. The lower limit of quantification was 200 pg/mL and the linear quantification range up to 5,000 pg/mL in ascites as biological matrix. Significant levels of sEpCAM were found in 39% of C+, 14% of C- and 13% of LC ascites samples. Higher concentrations of sEpCAM were detectable in C+ (mean: 1,015 pg/mL) than in C- (mean: 449 pg/mL; p = 0.04) or LC (mean: 326 pg/mL; p = 0.01). Soluble EpCAM concentration of 1 ng/mL significantly inhibited ADCC of PBMNCs on EpCAM overexpressing target cells. Elevated concentrations of sEpCAM can be found in a subgroup of C+ and also in a small group of C- patients. We consider that sEpCAM levels in different tumor entities and individual patients should be evaluated prior to applying anti-EpCAM antibody-based cancer therapies, since sEpCAM neutralizes catumaxomab activity, making therapy less efficient.

10 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ASAndreas Seeber
Andreas Seeber
IBIoana Braicu
Ioana Braicu
GUGerold Untergasser
Gerold Untergasser
MNMani Nassir
Mani Nassir
DFDominic Fong
Dominic Fong
GSGilbert Spizzo
Gilbert Spizzo
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab